The global immuno-oncology market is set to witness a growth rate of 21% in the next 5 years. Increasing incidence and ...

While the approval is a historic event for the BiTE drug class in solid tumours, the market share opportunity is restricted ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Despite having no symptoms, Linda’s commitment to preventive care led to a life-saving lung cancer diagnosis. Learn why early ...

Lung cancer patients can expect improved long term survival under a new treatment combination, according to new Irish research published today. The patients with lung cancer who received an ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

SMMT's HARMONi trial shows PFS benefits for ivonescimab in EGFR-mutant NSCLC, but lack of proven overall survival raises ...

CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with ...